Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Phase 2

Completed

Conditions: High Grade Upper Tract Urothelial Carcinoma

Interventions: Drug: Methotrexate
Drug: Gemcitabine
Drug: Vinblastine
Drug: Carboplatin
Drug: Doxorubicin
Drug: Cisplatin
Drug: Pegfilgrastim
Procedure: Nephroureterectomy

First Posted Date: 2015-04-09

Last Posted Date: 2023-07-10

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 36

Registration Number: NCT02412670

Locations: 🇺🇸
Illinois CancerCare-Canton, Canton, Illinois, United States
🇺🇸
Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸
Illinois CancerCare-Eureka, Eureka, Illinois, United States

and more 131 locations

A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Atezolizumab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2015-04-06

Last Posted Date: 2019-02-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 8

Registration Number: NCT02409355

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States
🇺🇸
Marin Cancer Care Inc, Greenbrae, California, United States

and more 79 locations

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Phase 3

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Drug: Carboplatin
Drug: Cisplatin
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2015-04-06

Last Posted Date: 2023-03-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 572

Registration Number: NCT02409342

Locations: 🇫🇷
Centre D'oncologie de Gentilly, Nancy, France
🇫🇷
Centre Hospitalier Regional Sud Reunion, Saint-pierre, France
🇧🇷
Centro de Pesquisas Clinicas em Oncologia - CPCO, Cachoeiro de Itapemirim, ES, Brazil

and more 139 locations

Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer

Not Applicable

Conditions: Pleural Effusion, Malignant

Interventions: Drug: cisplatin

First Posted Date: 2015-04-03

Last Posted Date: 2015-11-20

Lead Sponsor: Shantou University Medical College

Target Recruit Count: 50

Registration Number: NCT02407912

Locations: 🇨🇳
Department of medical oncology, Shantou, Guangdong, China

Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer

Phase 2

Completed

Conditions: Neoplasms

Interventions: Drug: Docetaxel
Drug: Cisplatin
Radiation: Radiotherapy

First Posted Date: 2015-03-31

Last Posted Date: 2020-06-02

Lead Sponsor: Mian XI

Target Recruit Count: 110

Registration Number: NCT02403531

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Extensive Stage Small Cell Lung Carcinoma
Limited Stage Small Cell Lung Carcinoma
Neuroendocrine Neoplasm

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Procedure: Radiation Therapy

First Posted Date: 2015-03-30

Last Posted Date: 2024-11-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 83

Registration Number: NCT02402920

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

The Impact of Pentoxifylline and Vitamin E on Radiotherapy-induced Toxicity in Head & Neck Cancer Patients

Phase 2

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: Pentoxifylline
Drug: Vitamin E
Drug: Cisplatin
Radiation: Radiation therapy

First Posted Date: 2015-03-25

Last Posted Date: 2019-11-26

Lead Sponsor: Ain Shams University

Target Recruit Count: 60

Registration Number: NCT02397486

Locations: 🇪🇬
Ain Shams University Hospitals, Cairo, Egypt

The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial

Phase 2

Completed

Conditions: Squamous Cell Carcinoma
Adenocarcinoma
Carcinoma, Adenosquamous
Uterine Cervical Neoplasms

Interventions: Drug: Metformin
Drug: Cisplatin
Drug: FAZA

First Posted Date: 2015-03-20

Last Posted Date: 2021-04-21

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 16

Registration Number: NCT02394652

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Centre Hospitalier De L'Université de Montréal, Montréal, Quebec, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 2 locations

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase 1

Terminated

Conditions: UC
MPN
Lung Cancer
Solid Tumor
Gastric Cancer
Urothelial Cancer
Endometrial Cancer
Multiple Myeloma
Myeloproliferative Neoplasms
Breast Cancer

Interventions: Drug: Pemigatinib
Drug: Docetaxel
Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Trastuzumab
Drug: Retifanlimab
Drug: Cisplatin

First Posted Date: 2015-03-19

Last Posted Date: 2023-01-06

Lead Sponsor: Incyte Corporation

Target Recruit Count: 201

Registration Number: NCT02393248

Locations: 🇺🇸
Ohio State University - Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States

and more 17 locations

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1

Active, not recruiting

Conditions: Breast Cancer
Triple-Negative Breast Cancer

Interventions: Drug: Romidepsin
Drug: Cisplatin
Drug: Nivolumab

First Posted Date: 2015-03-19

Last Posted Date: 2023-04-27

Lead Sponsor: Priyanka Sharma

Target Recruit Count: 51

Registration Number: NCT02393794

Locations: 🇺🇸
University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
🇺🇸
University of Kansas Cancer Center - West, Kansas City, Kansas, United States
🇺🇸
University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy